Moving care out of hospital appears to reach people unevenly, though this week's evidence only describes the problem

A thin week for new clinical evidence, and one that points one way. Two of the five clinical domains produced items, Therapies & AHPs and OPAT; nothing cleared the bar in Acute Frailty, Clinical Psychology or Palliative Care. The most useful item is guidance rather than a trial: the updated UK good practice recommendations for outpatient parenteral antimicrobial therapy, covered in its own signal, which add five recommendations including OPAT in hard-to-reach groups and equitable provision of care. Beside it sit two descriptive studies from outside the UK, one on post-acute allocation in Rome and one on rural veterans’ last weeks after discharge. They share a point: moving care out of hospital does not appear to reach people evenly, and how access is designed seems to shape who benefits. None of the three tests whether any change gives patients time back.

Equity of access is now a stated OPAT recommendation, but the data to audit it against have not been found

The updated recommendations, summarised by Noble and colleagues (J Antimicrob Chemother, 6 October 2026), were produced through a systematic literature review, expert consensus and consultation Guidance (Noble et al., PMID 42910527). Five are new: self-administration; OPAT in hard-to-reach groups; patient education; monitoring protocols for patients on complex oral antimicrobials and on new parenteral routes and regimens; and equitable provision of care. Two are amended, on thromboprophylaxis and on early collaboration with vascular access teams. Only the abstract was read, not the full recommendations, so what the hard-to-reach and equity recommendations require of services in practice is not yet established. For services in areas of high deprivation and in rural or dispersed settings they give something concrete to audit against, but no UK data on OPAT uptake by deprivation or rurality were found. The October monthly review reported an early signal that failures of self-administered OPAT cluster in a UK cohort; whether the new self-administration recommendation addresses who is selected cannot be told from the abstract. This week’s evidence carried no international comparator for OPAT access.

Where patients went after hospital in Rome tracked the hospital they left, and the study cannot say why

A retrospective observational study of 2,314 patients who needed a post-acute care pathway, assessed by physiotherapists at three hospitals within one Local Health Authority in Rome during 2024, found that hospital of origin was strongly associated with discharge setting (χ²=893.34, p<0.001; Cramér’s V=0.456) Audit/Data (Servadio et al., PMID 42776158). Home care was the most frequent setting at two hospitals and intensive rehabilitation at the third. The hospitals also differed significantly in age, length of stay, functional independence, cognition and health-related quality of life. The authors link the variation to patient case-mix and hospital-specific organisational characteristics, and suggest that physiotherapist-led functional assessment may support discharge planning, while saying that multicentre studies are needed to determine its effect on discharge appropriateness and long-term outcomes. It is single-authority Italian data and descriptive: it does not test whether standardised assessment changes outcomes, and it reports none after allocation, including function or time at home. It adds descriptive support, and no more, to the published pattern on handover and coordination fidelity limiting the benefit delivered. The published reading that process measures move while outcomes stay flat was not tested, because this study is process-level.

Rural veterans who died within a month of discharge describe distance, declined home services and carer strain

A qualitative analysis of clinical notes for 200 US Veterans Health Administration patients aged 65 and over, 100 rural and 100 urban, who were discharged home after a medical or neurological admission and died within 30 days, identified three themes that distinguished rural patients Primary Study (Randolph et al., PMID 42855931). These were geographic distance to care settings, with lengthy drive times; declining the offer of home health services; and high caregiver burden. The authors report that these experiences contributed to moments of discordance and uncertainty among patients, care teams and caregivers. The sample is deaths only, with no comparison with survivors, so the study is hypothesis-generating and gives no effect estimate; it is one US system, not a UK or dispersed-population evaluation. It extends, at low weight, the published pattern on remote care for dispersed populations and the published pattern that digital exclusion and carer capacity limit who benefits: the caregiver-burden theme fits that reading. The open question is whether the same pattern appears in survivors, and whether offering community services differently changes uptake.

A small case series shows how weekly dosing can enable OPAT, and does not change practice

A retrospective case series of eight adults given once-weekly rezafungin for difficult-to-treat Aspergillus infection, with cases supplied by experienced clinicians in Spain, the UK and Italy, used the drug mainly to enable OPAT where triazole resistance or intolerance would otherwise mean daily intravenous echinocandin Primary Study (Stone et al., PMID 42952321). Most had pulmonary aspergillosis; most improved or stabilised, the drug was well tolerated including in renal impairment, and one patient with chronic aspergilloma needed surgery. The authors report that it enabled OPAT and facilitated discharge. With eight clinician-selected cases, no comparator and only the abstract read, it is a niche antifungal option. It illustrates, for one indication, how a weekly-dosed agent can reduce how often a person must attend for infusion, which would matter most where distance limits visits; the series does not measure that.

This week’s evidence says little about whether patients’ time was well spent

No item tests the patient’s time directly. The three items point the same way: recommendations that name hard-to-reach groups, a rural cohort in which distance, declined home services and carer strain mark the last weeks after discharge, and post-acute allocation in Rome that differed by discharging hospital. All of those are costs in the person’s and the carer’s time, or in where that time is spent, and none is counted as such. No patient-reported outcome is carried by any of them beyond baseline measures in the Rome data. The only UK item is guidance; nothing tests any of it in populations of high deprivation or in dispersed rural settings, and the identified international material is largely US, Canadian, Australian or Singapore work in oncology, trauma or inpatient settings. That absence is the finding.

The national documents that would set direction are still outstanding

The interim product for the dementia and frailty framework, forecast for September, was not found published this week, and a search found nothing reporting that it has appeared; the commitment is recorded in last week’s synthesis, and the primary source was not re-read. No outcome of the consultation on the allied health professions framework, which closed on 18 September, was found either. National direction therefore remains pending, and the evidence to read it against is still mostly descriptive and from elsewhere.

Open questions

• Does standardising physiotherapist-led functional assessment reduce between-site variation in post-acute allocation, and does that change function or time at home?
• What do the new OPAT hard-to-reach and equitable-provision recommendations require of services in practice, and is there any UK data on OPAT uptake by deprivation or rurality?
• Would the rural distance, declined-home-health and caregiver-burden pattern appear in survivors, and does offering community services differently change uptake in dispersed populations?
• When the dementia and frailty framework interim appears, will it test frailty-specific flow and community-transfer measures against deprived and dispersed populations?